CCL2 and Alzheimer disease: It also inhibits and reverse monocyte differentiation to macrophages, greater than inhibition and reversion achieved with AD-MSC (Eiró et al., 2014), and also reduce tissue levels of IL-6, IL-8, IFN-γ, TNF-α, MCP-1, or MIP-1α mRNA, as well as increase of the anti-inflammatory interleukin IL-10 (at levels comparable to those achieved with dexamethasone treatment) (Bermudez et al., 2015, 2016; Sendon-Lago et al., 2019).